MiNK Therapeutics Identifies iNKT Cell Depletion as Key Mechanism in Advanced Idiopathic Pulmonary Fibrosis
Key Insights
MiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis (search).
The findings provide direct human tissue evidence supporting a mechanistic role for iNKT insufficiency in advanced IPF (search), potentially contributing to persistent inflammation and progressive fibrotic remodeling.
This research expands MiNK's iNKT platform into chronic fibrotic lung disease, complementing ongoing development programs in oncology, GVHD, and severe pulmonary inflammation.
MiNK Therapeutics has unveiled compelling translational data demonstrating that invariant natural killer T (iNKT) cell depletion represents a key mechanistic feature of advanced idiopathic pulmonary fibrosis (search) (IPF (search)), potentially opening new therapeutic avenues for this fatal lung disease. The findings were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology in Banff, Alberta, Canada.
Human Tissue Evidence Links iNKT Depletion to Advanced Disease
The research, led by Dr. Terese Hammond, Head of Pulmonary and Inflammatory Diseases at MiNK Therapeutics and a Pulmonary and Critical Care physician, analyzed human lung tissue to reveal significant depletion of iNKT cells (search) in lung-associated lymph nodes from patients with end-stage IPF (search) compared to donor controls.
"This work provides direct human tissue evidence that iNKT insufficiency is present in advanced IPF (search)," explained Dr. Hammond. "When considered alongside our prior clinical experience demonstrating immunomodulatory and tissue repair–associated activity of iNKT cell therapy in acute lung injury (search) and ARDS (search), these findings support the broader potential of MiNK's iNKT platform to address chronic immune-mediated lung disease."
Mechanistic Insights into Progressive Fibrosis
The data suggest that iNKT cell depletion represents the loss of a natural immunoregulatory mechanism that may contribute to persistent inflammation and progressive fibrotic remodeling, even in late-stage disease. iNKT cells (search) function as key regulators of immune homeostasis, and their absence appears to disrupt the delicate balance required for proper tissue repair and immune function.
These findings strengthen the translational rationale for iNKT cell replenishment strategies as a potential approach to restoring immune balance and supporting tissue repair in fibrotic lung disease.
Addressing a Critical Unmet Medical Need
IPF (search) represents one of the most challenging respiratory diseases, characterized by irreversible scarring of the lungs, progressive respiratory failure, and a median survival of 3-5 years. The disease affects approximately 100,000 patients in the United States, with 30,000-40,000 new diagnoses annually, representing a substantial global unmet medical need.
Currently, no approved treatment has demonstrated the ability to reverse fibrosis or restore immune balance in IPF (search) patients, highlighting the critical need for innovative therapeutic approaches.
Platform Expansion into Chronic Fibrotic Disease
The research significantly expands MiNK's iNKT platform relevance into chronic fibrotic and senescence-associated indications, complementing the company's ongoing development programs in oncology, graft-versus-host disease (search) (GVHD), and severe pulmonary inflammation.
MiNK's lead candidate, agenT-797, is an off-the-shelf allogeneic iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. The therapy functions as "master regulators," combining the cytotoxic capabilities of NK cells with T-cell-like antigen recognition and memory.
Current Clinical Development
AgenT-797 is currently being evaluated in Phase 1 trials for multiple indications, including solid tumors (search), relapsed/refractory multiple myeloma (search), graft-versus-host disease (search), and acute respiratory distress syndrome secondary to COVID-19 (search). The therapy is administered without lymphodepletion or Human Leukocyte Antigen (HLA) matching, potentially offering a more accessible treatment option.
The scalable, cryopreserved manufacturing process developed by MiNK Therapeutics in Lexington, Massachusetts, is designed to provide accessible, transformative treatment options for patients with difficult-to-treat conditions.